SCHEMBL2177641

SCHEMBL2177641

c1ccc(C(c2ccccc2)N2CCC3OC3C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
DPP4 P27487 1/20 0.46
OPRM1 P35372 5/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM5 P08912 1/20 0.44
ADRA2A P08913 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
CYP2D6 P10635 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
DRD1 P21728 1/20 0.44
ADRA1D P25100 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HRH1 P35367 1/20 0.44
DRD3 P35462 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2177322 0.83 CYP2D6 (0.55) OPRM1CYP2D6OPRL1OPRK1ALDH1A1
SCHEMBL2178968 0.81 CYP2D6 (0.40) L3MBTL3L3MBTL1DPP4MEN1KMT2A
SCHEMBL2180052 0.80 OPRM1 (0.46) DPP4OPRM1CYP2D6OPRL1OPRK1
SCHEMBL2177597 0.79 OPRM1 (0.49) DPP4OPRM1OPRL1OPRK1OPRD1
SCHEMBL2177483 0.77 SLC6A4 (0.56) MEN1KMT2ACYP2D6HTR2AHTR2C
SCHEMBL19075528 0.76 DPP4 (0.52) L3MBTL3L3MBTL1DPP4OPRM1MEN1
SCHEMBL19075614 0.76 DPP4 (0.52) L3MBTL3L3MBTL1DPP4OPRM1MEN1
SCHEMBL2267306 0.75 L3MBTL3 (0.53) L3MBTL3L3MBTL1DPP4OPRM1MEN1
SCHEMBL2267354 0.75 L3MBTL3 (0.53) L3MBTL3L3MBTL1DPP4OPRM1MEN1
SCHEMBL13699664 0.75 L3MBTL3 (0.53) L3MBTL3L3MBTL1DPP4OPRM1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2351738-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO)PIPERIDIN-3-OL Sumitomo Chemical Company, Limited (JP) 2011-08-03 EP disclosed
US-20110172431-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-14 US disclosed
US-20110166357-A1 METHOD FOR PRODUCING N-SUBSTITUTED-TRANS-4-AZIDOPIPERIDINE-3-OL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166357-A1 METHOD FOR PRODUCING N-SUBSTITUTED-TRANS-4-AZIDOPIPERIDINE-3-OL RPS27L, OSGEP, RPLP1 L3MBTL3 2650/4885L3MBTL1 2186/4885DPP4 4436/4885
US-20110172431-A1 PROCESS FOR PRODUCING 1-SUBSTITUTED TRANS-4-(SUBSTITUTED AMINO) PIPERIDIN-3-OL TEAD4, TEAD3, TEAD2 L3MBTL3 4007/4885L3MBTL1 3828/4885DPP4 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.